Stock Price
36.39
Daily Change
0.22 0.61%
Monthly
-0.30%
Yearly
50.87%
Q1 Forecast
35.29



Peers Price Chg Day Year Date
Terumo 2,070.00 -1.50 -0.07% -25.18% Mar/16
Abbott 108.03 -0.11 -0.10% -14.74% Mar/13
AngioDynamics 10.60 -0.11 -1.03% 17.65% Mar/13
Accuray 0.37 -0.05 -11.88% -79.78% Mar/13
AtriCure 29.85 0.32 1.07% -10.39% Mar/13
Baxter International 17.40 -0.61 -3.39% -49.70% Mar/13
Becton, Dickinson and Co. 159.36 -0.27 -0.17% -29.48% Mar/13
Boston Scientific 69.13 0.58 0.85% -28.85% Mar/13
Artivion 36.39 0.22 0.61% 50.87% Mar/13
Edwards Lifesciences 81.81 -2.80 -3.31% 18.07% Mar/13

Indexes Price Day Year Date
US2000 2480 -8.94 -0.36% 21.33% Mar/13

Artivion Inc traded at $36.39 this Friday March 13th, increasing $0.22 or 0.61 percent since the previous trading session. Looking back, over the last four weeks, Artivion gained 0.30 percent. Over the last 12 months, its price rose by 50.87 percent. Looking ahead, we forecast Artivion Inc to be priced at 35.29 by the end of this quarter and at 32.19 in one year, according to Trading Economics global macro models projections and analysts expectations.

CryoLife, Inc. (CryoLife), is a medical device company. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.